



CS/BSE/NSE/PR/2018-2019
October 23, 2018

To
The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

To
The General Manager
Department of Corporate Services
BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai - 400 001

Stock Code: SUVEN - EQ

Stock Code: 530239

Dear Sir/Madam,

Sub: Press Release

.....
With reference to above subject, please find enclosed Press Release of our company titled ***“Suvan to present at 11TH CLINICAL TRIALS ON ALZHEIMER'S DISEASE (CTAD) during October 24-27, 2018 - BARCELONA, SPAIN”***.

This is for your information and record.

Thanking You,
Yours faithfully,
For **Suvan Life Sciences Limited**

A handwritten signature in black ink, appearing to read "K. Hanumantha Rao".

K. Hanumantha Rao
Company Secretary

Suvan Life Sciences Limited

Registered Office: 8-2-334 | SDE Serene Chambers | 6th Floor Road No.5 | Avenue 7
Banjara Hills | Hyderabad – 500 034 | Telangana | India | CIN: L24110TG1989PLC009713
Tel: 91 40 2354 1142/ 3311/ 3315 Fax: 91 40 2354 1152 Email: info@suvan.com website: www.suvan.com

News Release

Suven to present at 11TH CLINICAL TRIALS ON ALZHEIMER'S DISEASE (CTAD) during October 24-27, 2018 - BARCELONA, SPAIN

HYDERABAD, INDIA (October 23, 2018) – Suven Life Sciences is participating and presenting the baseline patient demographics and scales from the ongoing phase-2a proof-of-concept trial of SUVN-502 for moderate Alzheimer's Disease at **11TH CLINICAL TRIALS ON ALZHEIMER'S DISEASE (CTAD)** during October 24-27, 2018 at BARCELONA, SPAIN

SUVN-502 is a promising pure, 5-HT₆ receptor antagonist in development for the treatment of moderate Alzheimer's disease, a novel triple combination treatment approach.

This trial evaluates the efficacy and safety of SUVN-502 added to background stable donepezil and memantine, a triple therapy in subjects with moderate AD dementia.

At CTAD, Suven is presenting the baseline patient demographics and scales from the ongoing phase-2a proof-of-concept trial of SUVN-502 for moderate Alzheimer's disease.

Top-line efficacy results from this study are expected during August/September of 2019

About Suven Life Sciences

Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies using GPCR targets. Suven has 4 clinical stage compounds, a Phase 2 undergoing SUVN-502, Phase 2 ready SUVN-G3031, Phase 1 completed SUVN-D4010, Phase 1 commenced SUVN-911 and Phase 1 ready SUVN-I6107.

In addition to these clinical compounds the Company has nine (9) internally-discovered therapeutic drug candidates currently in various stages of pre-clinical development targeting conditions such as ADHD, dementia, depression, Huntington's disease, Parkinson's disease and pain.

For more information please visit our Web site at <http://www.suven.com>

Risk Statement:

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive; Suven may not undertake to update any forward-looking statements that may be made from time to time.

Suven Life Sciences Limited

Registered Office: 8-2-334 | SDE Serene Chambers | 6th Floor, Road No.5 | Avenue 7
Banjara Hills | Hyderabad – 500 034 | Telangana | India | CIN: L24110TG1989PLC009713
Tel: 91 40 2354 1142/ 3311/ 3315 Fax: 91 40 2354 1152 Email: info@suven.com website: www.suven.com